<DOC>
	<DOCNO>NCT00214838</DOCNO>
	<brief_summary>The primary objective study identify maximum tolerate dose evaluate safety atiprimod patient advance cancer .</brief_summary>
	<brief_title>An Open-Label Study Safety Efficacy Atiprimod Treatment Patients With Advanced Cancer</brief_title>
	<detailed_description>The primary objective study identify maximum tolerate dose ( MTD ) evaluate safety atiprimod patient advance cancer . The secondary objective study 1 ) measure pharmacokinetics atiprimod 2 ) evaluate efficacy atiprimod treatment patient advance cancer 3 ) compare pharmacokinetics atiprimod tablet capsule start dose , intent switch capsule dose escalation capsule pose safety issue .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histological proof advance cancer must fail relapse follow standard therapy standard therapy available . estimate life expectancy least 12 week . must evaluable disease . ECOG ( Zubrod ) PS 0 2 sign inform consent . age 13 year time signing informed consent . renal insufficiency concomitant radiotherapy , chemotherapy investigational therapy . peripheral neuropathy grade 3 great ( NCI CTC version 3 grading ) evidence clinically significant mucosal internal bleeding condition opinion investigator , place patient unacceptable risk he/she participate study . clinically relevant active infection serious comorbid medical condition . atiprimod potent inhibitor CYP2D6 , patient take drug substrate CYP2D6 ( e.g . beta blocker , antidepressant antipsychotic exclude .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>cancer , atiprimod</keyword>
</DOC>